Reviva Pharmaceuticals will present negative symptom data for brilaroxazine at CNS Summit 2025, focusing on schizophrenia treatment efficacy.
Quiver AI Summary
Reviva Pharmaceuticals Holdings, Inc. announced that it will present negative symptom data for its drug brilaroxazine at the upcoming CNS Summit 2025 in Boston, taking place from November 2-5. This presentation will cover findings from the Phase 3 RECOVER trial involving patients with acute exacerbation of schizophrenia, as well as long-term results from an open-label extension study in stable schizophrenia patients. The poster presentation is titled "Brilaroxazine Treatment Effect on Negative Symptoms in Schizophrenia: RECOVER Trial in Acute and Stable Patients Over 1 Year" and will occur on November 3rd and 4th. Reviva focuses on developing therapies addressing unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a pipeline that includes brilaroxazine and another candidate, RP1208, both protected by patents in multiple regions.
Potential Positives
- Reviva Pharmaceuticals will present significant data on brilaroxazine at the prestigious CNS Summit 2025, highlighting ongoing research and commitment to addressing schizophrenia symptoms.
- The poster presentation will detail both acute and long-term effects of brilaroxazine, potentially reinforcing its clinical efficacy and strengthening the company's position in the CNS therapeutic area.
- Reviva's pipeline includes innovative drug candidates that have received patents in multiple regions, showcasing the company's commitment to developing novel therapies and protecting its intellectual property.
Potential Negatives
- Presentation of negative symptom data from brilaroxazine may raise concerns about the drug's efficacy and impact investor confidence.
- Disclosure of disappointing trial results could lead to increased scrutiny from stakeholders and potential regulatory challenges.
- The emphasis on unmet medical needs juxtaposed with negative data may suggest that the company's current pipeline is not meeting expectations, questioning the viability of its future products.
FAQ
What is the purpose of the RECOVER trial data presentation?
The presentation aims to share findings on brilaroxazine's effect on negative symptoms in schizophrenia patients.
When and where will the CNS Summit 2025 be held?
The CNS Summit 2025 will take place in Boston, Massachusetts, from November 2-5, 2025.
What are the main therapeutic areas Reviva focuses on?
Reviva focuses on central nervous system, inflammatory, and cardiometabolic diseases.
What are the drug candidates in Reviva's pipeline?
Reviva's pipeline includes brilaroxazine (RP5063) and RP1208, both discovered in-house.
Who should be contacted for investor relations at Reviva?
For investor relations, contact PJ Kelleher at LifeSci Advisors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that negative symptom data for brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-term open-label extension trial in clinically stable schizophrenia patients will be presented as a poster presentation at the CNS Summit 2025, taking place November 2-5, in Boston, Massachusetts.
Details for the poster presentation can be found below:
Title: Brilaroxazine Treatment Effect on Negative Symptoms in Schizophrenia: RECOVER Trial in Acute and Stable Patients Over 1 Year
Poster Number: 32
Date and Time: Monday, November 3 rd and Tuesday November 4 th from 5:00- 7:00 PM ET
Abstracts and additional details can be found at the CNS Summit 2025 website .
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
[email protected]
